Vir Biotechnology to present data on elebsiran and tobevibart for hepatitis delta at AASLD meeting

Vir Biotechnology will present expanded Phase 2 SOLSTICE trial results for its combination of elebsiran and tobevibart in chronic hepatitis delta at the American Association for the Study of Liver Diseases' The Liver Meeting 2026 in Denver, November 5-9.